Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
University of Mississippi
mi
from
Jackson, MS
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
University of Mississippi
mi
from
Jackson, MS
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
Albany Medical College
mi
from
Albany, NY
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
Albany Medical College
mi
from
Albany, NY
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
Cleveland Clinic
mi
from
Cleveland, OH
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
Medical University of South Carolina
mi
from
Charleston, SC
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
Memorial Hospital
mi
from
Chattanooga, TN
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
Memorial Hospital
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
Erlanger Hospital
mi
from
Chattanooga, TN
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
Erlanger Hospital
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
Dallas VA Medical Center
mi
from
Dallas, TX
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
Dallas VA Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
The University Of Texas
mi
from
Houston, TX
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
The University Of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
Inova Health Care Services
mi
from
Falls Church, VA
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
Inova Health Care Services
mi
from
Falls Church, VA
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
University of Wisconsin
mi
from
Madison, WI
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
University of California, San Diego
mi
from
San Diego, CA
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
University of Florida
mi
from
Gainesville, FL
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
Northwestern University
mi
from
Chicago, IL
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
Washington University
mi
from
Saint Louis, MO
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
Mount Sinai School of Medicine
mi
from
New York, NY
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
Sanford Health
mi
from
Fargo, ND
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
Sanford Health
mi
from
Fargo, ND
Click here to add this to my saved trials
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
Optimization of NULOJIX® (Belatacept) Usage as a Means of Avoiding CNI and Steroids in Renal Transplantation (CTOT-10)
Status: Enrolling
Updated:  8/29/2017
Emory University
mi
from
Atlanta, GA
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
Optimization of NULOJIX® (Belatacept) Usage as a Means of Avoiding CNI and Steroids in Renal Transplantation (CTOT-10)
Status: Enrolling
Updated: 8/29/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
Optimization of NULOJIX® (Belatacept) Usage as a Means of Avoiding CNI and Steroids in Renal Transplantation (CTOT-10)
Status: Enrolling
Updated:  8/29/2017
University of Alabama
mi
from
Birmingham, AL
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
Optimization of NULOJIX® (Belatacept) Usage as a Means of Avoiding CNI and Steroids in Renal Transplantation (CTOT-10)
Status: Enrolling
Updated: 8/29/2017
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
Optimization of NULOJIX® (Belatacept) Usage as a Means of Avoiding CNI and Steroids in Renal Transplantation (CTOT-10)
Status: Enrolling
Updated:  8/29/2017
University of California at San Francisco
mi
from
San Francisco, CA
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
Optimization of NULOJIX® (Belatacept) Usage as a Means of Avoiding CNI and Steroids in Renal Transplantation (CTOT-10)
Status: Enrolling
Updated: 8/29/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Acid-Base Compensation in Chronic Kidney Disease
Acid-Base Compensation in Chronic Kidney Disease: Measurement and Physiologic Impact
Status: Enrolling
Updated:  8/29/2017
Duke University School of Medicine
mi
from
Durham, NC
Acid-Base Compensation in Chronic Kidney Disease
Acid-Base Compensation in Chronic Kidney Disease: Measurement and Physiologic Impact
Status: Enrolling
Updated: 8/29/2017
Duke University School of Medicine
mi
from
Durham, NC
Click here to add this to my saved trials
Study of LY3016859 in Participants With Diabetic Nephropathy
Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients
Status: Enrolling
Updated:  9/7/2017
Innovative Research of West Florida, Inc.
mi
from
Clearwater, FL
Study of LY3016859 in Participants With Diabetic Nephropathy
Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients
Status: Enrolling
Updated: 9/7/2017
Innovative Research of West Florida, Inc.
mi
from
Clearwater, FL
Click here to add this to my saved trials
Study of LY3016859 in Participants With Diabetic Nephropathy
Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients
Status: Enrolling
Updated:  9/7/2017
Creighton University Medical Center
mi
from
Omaha, NE
Study of LY3016859 in Participants With Diabetic Nephropathy
Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients
Status: Enrolling
Updated: 9/7/2017
Creighton University Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of LY3016859 in Participants With Diabetic Nephropathy
Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients
Status: Enrolling
Updated:  9/7/2017
Northeast Clinical Research Center, LLC
mi
from
Bethlehem, PA
Study of LY3016859 in Participants With Diabetic Nephropathy
Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients
Status: Enrolling
Updated: 9/7/2017
Northeast Clinical Research Center, LLC
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Study of LY3016859 in Participants With Diabetic Nephropathy
Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients
Status: Enrolling
Updated:  9/7/2017
Southeast Renal Research Institute
mi
from
Chattanooga, TN
Study of LY3016859 in Participants With Diabetic Nephropathy
Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients
Status: Enrolling
Updated: 9/7/2017
Southeast Renal Research Institute
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Study of LY3016859 in Participants With Diabetic Nephropathy
Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients
Status: Enrolling
Updated:  9/7/2017
TAD Clinical Research
mi
from
Lufkin, TX
Study of LY3016859 in Participants With Diabetic Nephropathy
Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients
Status: Enrolling
Updated: 9/7/2017
TAD Clinical Research
mi
from
Lufkin, TX
Click here to add this to my saved trials
Study of LY3016859 in Participants With Diabetic Nephropathy
Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients
Status: Enrolling
Updated:  9/7/2017
Renal Associates, PA
mi
from
San Antonio, TX
Study of LY3016859 in Participants With Diabetic Nephropathy
Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients
Status: Enrolling
Updated: 9/7/2017
Renal Associates, PA
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of LY3016859 in Participants With Diabetic Nephropathy
Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients
Status: Enrolling
Updated:  9/7/2017
mi
from
Sofia,
Study of LY3016859 in Participants With Diabetic Nephropathy
Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients
Status: Enrolling
Updated: 9/7/2017
mi
from
Sofia,
Click here to add this to my saved trials
Allopurinol for Renal Transplant Associated Hypertension in Children
Randomized Double-blinded, Placebo-controlled, Cross-over Trial of Allopurinol for the Treatment of Post-renal-transplant Hypertension in Children
Status: Enrolling
Updated:  9/12/2017
Texas Children's Hospital
mi
from
Houston, TX
Allopurinol for Renal Transplant Associated Hypertension in Children
Randomized Double-blinded, Placebo-controlled, Cross-over Trial of Allopurinol for the Treatment of Post-renal-transplant Hypertension in Children
Status: Enrolling
Updated: 9/12/2017
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab
Immunophenotyping and Functional Profiles of Peripheral Lymphocytes in Renal Transplant Recipients After T-cell Depletion With Alemtuzumab (Anti-CD52 Monoclonal Antibody)-Potential Implications for Safe Immunosuppressive Minimization
Status: Enrolling
Updated:  9/12/2017
Northwestern Memorial Hospital
mi
from
Chicago, IL
Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab
Immunophenotyping and Functional Profiles of Peripheral Lymphocytes in Renal Transplant Recipients After T-cell Depletion With Alemtuzumab (Anti-CD52 Monoclonal Antibody)-Potential Implications for Safe Immunosuppressive Minimization
Status: Enrolling
Updated: 9/12/2017
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects
A Phase 1, Non-randomized, Parallel-group, Open-label Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects
Status: Enrolling
Updated:  9/13/2017
Clinical Research Facility
mi
from
Minneapolis, MN
Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects
A Phase 1, Non-randomized, Parallel-group, Open-label Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects
Status: Enrolling
Updated: 9/13/2017
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit
Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit
Status: Enrolling
Updated:  9/13/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit
Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit
Status: Enrolling
Updated: 9/13/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Isotonic Solutions and Major Adverse Renal Events Trial in the Non-Medical Intensive Care Unit (SMART-SURG)
Isotonic Solutions and Major Adverse Renal Events Trial in Non-Medical Intensive Care Units
Status: Enrolling
Updated:  9/13/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Isotonic Solutions and Major Adverse Renal Events Trial in the Non-Medical Intensive Care Unit (SMART-SURG)
Isotonic Solutions and Major Adverse Renal Events Trial in Non-Medical Intensive Care Units
Status: Enrolling
Updated: 9/13/2017
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis
Randomized Study of Standard vs High Amount of Hemodialysis Using Low vs High Flux Dialyzer Membranes for End Stage Renal Disease
Status: Enrolling
Updated:  9/13/2017
University of Rochester School of Medicine
mi
from
Rochester, NY
Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis
Randomized Study of Standard vs High Amount of Hemodialysis Using Low vs High Flux Dialyzer Membranes for End Stage Renal Disease
Status: Enrolling
Updated: 9/13/2017
University of Rochester School of Medicine
mi
from
Rochester, NY
Click here to add this to my saved trials
Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients
Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients
Status: Enrolling
Updated:  9/13/2017
University of Michigan Hospital
mi
from
Ann Arbor, MI
Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients
Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients
Status: Enrolling
Updated: 9/13/2017
University of Michigan Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Cognitive Behavioral Treatment of Depression in ESRD Patients on Dialysis
Status: Enrolling
Updated:  9/14/2017
Parkside Hemodialysis
mi
from
Brooklyn, NY
Cognitive Behavioral Treatment of Depression in ESRD Patients on Dialysis
Status: Enrolling
Updated: 9/14/2017
Parkside Hemodialysis
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Saline Against Lactated Ringers or Plasmalyte in the Emergency Department
Saline Against Lactated Ringers or Plasmalyte in the Emergency Department (SaLt-ED)
Status: Enrolling
Updated:  9/14/2017
Vanderbilt University Medical Center Adult Emergency Department
mi
from
Nashville, TN
Saline Against Lactated Ringers or Plasmalyte in the Emergency Department
Saline Against Lactated Ringers or Plasmalyte in the Emergency Department (SaLt-ED)
Status: Enrolling
Updated: 9/14/2017
Vanderbilt University Medical Center Adult Emergency Department
mi
from
Nashville, TN
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
University of Alabama at Birmingham School of Medicine
mi
from
Birmingham, AL
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
University of Alabama at Birmingham School of Medicine
mi
from
Birmingham, AL
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Banner Good Samaritan Transplant
mi
from
Phoenix, AZ
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Banner Good Samaritan Transplant
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Cedars-Sinai Health System/Center for Kidney Diseases and Transplantation
mi
from
Los Angeles, CA
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Cedars-Sinai Health System/Center for Kidney Diseases and Transplantation
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
University of California at San Francisco
mi
from
San Francisco, CA
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Northwestern University
mi
from
Chicago, IL
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Southern Illinois University
mi
from
Springfield, IL
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Southern Illinois University
mi
from
Springfield, IL
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Indiana University
mi
from
Indianapolis, IN
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Maine Medical Center
mi
from
Portland, ME
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Maine Medical Center
mi
from
Portland, ME
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
University of Maryland Medical Center
mi
from
Baltimore, MD
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated:  9/17/2017
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)
Status: Enrolling
Updated: 9/17/2017
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials